Aspirin and clopidogrel in acute coronary syndromes: Therapeutic insights from the CURE study

Archives of Internal Medicine

Volumn 163, Issue 10, 2003, Pages 1145-1153

  Jneid, Hani ^a   Bhatt, Deepak L ^b   Corti, Roberto ^c   Badimon, Juan J ^c   Fuster, Valentin ^c   Francis, Gary S ^b  

^a University of Louisville School of Medicine   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; THIENO[3,2 C]PYRIDINE DERIVATIVE; THROMBOXANE A2; TICLOPIDINE;

ATHEROSCLEROTIC PLAQUE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG MECHANISM; GASTROINTESTINAL HEMORRHAGE; GENOMICS; HEART INFARCTION; HUMAN; MULTICENTER STUDY; NEUTROPENIA; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOGENESIS; UNSTABLE ANGINA PECTORIS; URINE LEVEL;

ACUTE DISEASE; ASPIRIN; CORONARY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; SYNDROME; TICLOPIDINE;

EID: 0037906337     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.10.1145     Document Type: Review

References (72)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
2. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med. 2001;134:224-238.
3. Badimon JJ, Zaman A, Helft G, Fayad Z, Fuster V. Acute coronary syndromes: pathophysiology and preventive priorities. Thromb Haemost. 1999;82: 997-1004.
4. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-235.
5. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet. 1999;353(suppl 2): SII5-9.
6. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775-778.
7. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594-599.
8. Cannon CP, Fuster V. Thrombogenesis, antithrombotic, and thrombolytic therapy. In: Fuster V, Alexander RW, O'Rourke RA, eds. Hurst's The Heart. 10th ed. New York, NY: McGraw-Hill Book Co; 2001:1373-1436.
9. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
10. Davies MJ. Stability and instability: two faces of coronary atherosclerosis: the Paul Dudley White Lecture 1995. Circulation. 1996;94:2013-2020.
11. De Reynal B, Francon F. Aspirin still stands [in French]. J Beige Rhumatol Med Phys. 1965;20: 197-204.
12. Flower RJ, Vane JR. Analgesic-antipyretics and anti-inflammatory agents: drugs employed in the treatment of gout. In: Gilman AG, Goodman IS, Rall TW, Murad F, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 7th ed. New York, NY: Macmillan; 1995:674-675.
13. Craven L. Experiences with aspirin (acetylsalicyclic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J. 1953;75:38-40.
14. Weiss HJ, Aledort LM. Impaired plateletconnective-tissue reaction in man after aspirin ingestion. Lancet. 1967;2:495-497.
15. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-235.
16. Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol. 1971;231:237-239.
17. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975;72:2994-2998.
18. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663-665.
19. Mann CO. The Aspirin Wars: Money, Medicine and 100 Years of Rampant Competition. New York, NY: Alfred Knopf Inc; 1991.
20. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets, I: acetylation of a particulate fraction protein. J Clin Invest. 1975; 56:624-632.
21. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978;61:314-319.
22. Fuster V, Dyken ML, Vokonas PS, Hennekens C, for the Special Writing Group. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87:659-675.
23. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and other platelet-active drugs: the relationship between dose, effectiveness, and side effects. Chest. 1992;102(suppl 4):327S-336S.
24. Patrignani, P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-1372.
25. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69:180-186.
26. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
27. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
28. Wu R, Lamontagne D, de Champlain J. Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation. 2002;105:387-392.
29. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
30. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
31. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309:396-403.
32. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2: 349-360.
33. Steering Committee of the Physicians' Health Study Research Group. Final Report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
34. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233-241.
35. Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
36. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997; 96:2751-2753.
37. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001; 85:265-271.
38. Peto R, Gray R, Collins R, Wheatley K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296:313-316.
39. Jneid H, Thacker HL. Coronary artery disease in women: different, often undertreated. Cleve Clin J Med. 2001;68:441-448.
40. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266:521-527.
41. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA. 2001;286:1187-1194.
42. Gorelick PB, Born GV, D'Agostino RB, Hanley DF Jr, Moye L, Pepine CJ. Therapeutic benefit: aspirin revisited in light of the introduction of clopidogrel. Stroke. 1999;30:1716-1721.
43. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999;25(suppl 2):15-19.
44. Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol. 2000;20:2316-2321.
45. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215-1220.
46. Balsano F, Rizzon P, Violi F, et al, for the Studio della Ticlopidina nell'Angina Instabile Group. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation. 1990;82:17-26.
47. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
48. Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel: clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med. 1998;3:257-260.
49. Caro JJ, Migliaccio-Wallek, for the CAPRA (CAPRIE [clopidogrel versus aspirin in patients at risk of ischaemic events] Actual Practice Rates Analysis) Study Group. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. Am J Med. 1999;107:568-572.
50. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 2001;103:363-368.
51. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation. 1999;99:2364-2366.
52. Berger PB, Bell MR, Rihal CS, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol. 1999;34:1891-1894.
53. Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation. 2000; 101:590-593.
54. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation. 2001;104:539-543.
55. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773-1777.
56. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
57. Bhatt DL, Bertrand ME, Berger PB, et al. Metaanalysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 2002;39:9-14.
58. Herbert JM, Dol F, Bernat A, Falotico R, Lale A, Savi P. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost. 1998;80:512-518.
59. Bossavy JP, Thalamas C, Sagnard L, et al. A doubleblind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood. 1998;92:1518-1525.
60. Moshfegh K, Redondo M, Julmy F, et al. Antiplatelet effects of clopidogrel compared with aspidn pirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol. 2000;36:699-705.
61. Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme: rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21:2033-2041.
62. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
63. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
64. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with Creactive protein. Am J Cardiol. 2001;88:672-674.
65. Assali AR, Salloum J, Sdringola S, et al. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Am J Cardiol 2001;88:884-886.
66. Topol EJ. The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome. Clin Cardiol. 2000;23(suppl 6): VI-23-VI-28.
67. Kastrati A, Schomig A, Seyfarth M, et al. PIA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation. 1999;99:1005-1010.
68. Nurden AT. Platelet glycoprotein IIIa polymorphism and coronary thrombosis. Lancet. 1997; 350:1189-1191.
69. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 1997;350:1217-1219.
70. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002; 105:1650-1655.
71. Executive Summary of the Third Report of the Na-. tional Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486.
72. Bhatt D, Marso S, Hirsch A, Ringleb, P, Topol E. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002; 90:625-628.